Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, a study has ...

A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.